Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Bolt Biotherapeutics, Inc. BOLT
$1.75
+$0.16 (9.38%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
61052870.00000000
-
week52high
2.72
-
week52low
1.18
-
Revenue
5729000
-
P/E TTM
-1
-
Beta
0.99062800
-
EPS
-2.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Market Perform | Outperform | 11 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 17 мая 2022 г. |
| Morgan Stanley | Equal-Weight | Overweight | 06 янв 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 ноя 2021 г. |
| SVB Leerink | Outperform | Outperform | 16 авг 2021 г. |
| HC Wainwright & Co. | Buy | 04 окт 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| LAPORTE KATHLEEN | A | 25000 | 25000 | 14 дек 2022 г. |
| MILLER RICHARD A MD | A | 25000 | 25000 | 14 дек 2022 г. |
| Berner Laura | A | 12261 | 12261 | 14 дек 2022 г. |
| Berner Laura | A | 50000 | 50000 | 14 дек 2022 г. |
| Novo Holdings A/S | D | 3703991 | 800000 | 13 июл 2022 г. |
| SHAH MAHENDRA | A | 25000 | 25000 | 10 июн 2022 г. |
| O'CALLAGHAN BRIAN | A | 25000 | 25000 | 10 июн 2022 г. |
| ONETTO NICOLE | A | 25000 | 25000 | 10 июн 2022 г. |
| Lee Frank D. | A | 25000 | 25000 | 10 июн 2022 г. |
| MILLER RICHARD A MD | A | 25000 | 25000 | 10 июн 2022 г. |
Новостная лента
Bolt Biotherapeutics to Present at February Investor Conferences
GlobeNewsWire
01 февр 2023 г. в 08:00
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in February:
Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
GlobeNewsWire
31 авг 2022 г. в 07:30
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 12:20 p.m. ET (9:20 a.m. PT) in New York, New York.
Bolt Biotherapeutics: A Promised Follow Up
Seeking Alpha
26 авг 2022 г. в 15:24
Today, we post a promised follow-up on early stage biotech concern Bolt Biotherapeutics. The company has suffered some setbacks over the past year, but the stock now trades for approximately one-third of the cash on its balance sheet.
Bolt, Orion-E to build solar plants in Brazil for about $630 million
Reuters
23 авг 2022 г. в 16:34
Energy infrastructure company Orion-E has reached an agreement with energy trader Bolt to build solar photovoltaic plants in Brazil with a combined capacity of 500 megawatts (MW), a company executive said on Tuesday.
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022
GlobeNewsWire
27 мая 2022 г. в 08:00
- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present -